<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171873</url>
  </required_header>
  <id_info>
    <org_study_id>CSMS995ADE05</org_study_id>
    <nct_id>NCT00171873</nct_id>
    <nct_alias>NCT00202085</nct_alias>
  </id_info>
  <brief_title>Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut</brief_title>
  <official_title>Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmen Schade-Brittinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <brief_summary>
    <textblock>
      Placebo-controlled prospective randomized phase III study to investigate the
      antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of
      the midgut
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2001</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Median time to tumor progression at the time of the planned interim analysis that includes all data observed until June 2008.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rates According to World Health Organization (WHO) Criteria at 3 Month Intervals</measure>
    <time_frame>at 3 month intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Response at 3 Month Intervals</measure>
    <time_frame>at 3 month intervals up to 18 moths</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Control at 3 Month Intervals</measure>
    <time_frame>at 3 month intervals up to 18 moths</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Standardized Questionnaire) at Three-month Intervals in Comparison With the Start of the Study</measure>
    <time_frame>at three-month intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>at least on a monthly basis</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Octreotide LAR (Long Acting Release)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octreotide LAR 30 mg intramuscularly every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - Sodium chloride intramuscularly every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide LAR (Long-acting release)</intervention_name>
    <description>30 mg intramuscularly every 28 days</description>
    <arm_group_label>Octreotide LAR (Long Acting Release)</arm_group_label>
    <other_name>SMS995</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium chloride intramuscularly every 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Therapy-naive patients with histologically confirmed diagnosis of a locally inoperable
             or metastasized well-differentiated neuroendocrine tumor of the midgut

          -  curative surgery impossible

          -  two-dimensional tumor formation assessable by Computed Tomography (CT) or Magnetic
             Resonance Imaging (MRI)

          -  Age â‰¥ 18

          -  Karnofsky-index &gt; 60

          -  written informed consent

          -  proliferation index for Ki67

        Exclusion Criteria:

          -  hypersensitivity to octreotide

          -  poorly differentiated or small cell neuroendocrine tumors

          -  primary tumor outside of the midgut

          -  prior treatment with somatostatin-analogue &gt; 4 weeks

          -  prior treatment with alpha-interferon, chemotherapy, or chemoembolisation

          -  participation in any other clinical trial

          -  pregnancy or lactation

          -  no secondary malignancy in anamnesis; with the exception of patients without any
             manifestation of the secondary malignancy (without relapse) after curative therapy
             within the last five years

          -  severe decompensated organ malfunction (heart-, liver- insufficiency)

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rudolf Arnold, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philipps University Marburg Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>February 28, 2011</results_first_submitted>
  <results_first_submitted_qc>February 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2011</results_first_posted>
  <last_update_submitted>May 8, 2012</last_update_submitted>
  <last_update_submitted_qc>May 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Philipps University Marburg Medical Center</investigator_affiliation>
    <investigator_full_name>Carmen Schade-Brittinger</investigator_full_name>
    <investigator_title>Sponsor-representative</investigator_title>
  </responsible_party>
  <keyword>Double blind</keyword>
  <keyword>Phase III</keyword>
  <keyword>Disease</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>Octreotide</keyword>
  <keyword>Neuroendocrine tumor</keyword>
  <keyword>Cancer</keyword>
  <keyword>Tumor</keyword>
  <keyword>Midgut</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Octreotide LAR (SMS995)</title>
          <description>Octreotide LAR (Long-acting release) 30 mg intramuscularly every 28 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Sodium chloride intramuscularly every 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switched to Octreotide</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Octreotide LAR (SMS995)</title>
          <description>Octreotide LAR (Long-acting release) 30 mg intramuscularly every 28 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Sodium chloride intramuscularly every 28 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" lower_limit="38" upper_limit="79"/>
                    <measurement group_id="B2" value="61" lower_limit="39" upper_limit="82"/>
                    <measurement group_id="B3" value="62" lower_limit="38" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)</title>
        <description>Median time to tumor progression at the time of the planned interim analysis that includes all data observed until June 2008.</description>
        <time_frame>Up to 7 years</time_frame>
        <population>Conservative Intent to Treat (ITT) population consisting of all participants who received study drug. 3 participants in the Octreotide group and 1 participant in the placebo group without liver involvement at the beginning of the study were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Octreotide LAR (SMS995)</title>
            <description>Octreotide LAR (Long-acting release) 30 mg intramuscularly every 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sodium chloride intramuscularly every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)</title>
          <description>Median time to tumor progression at the time of the planned interim analysis that includes all data observed until June 2008.</description>
          <population>Conservative Intent to Treat (ITT) population consisting of all participants who received study drug. 3 participants in the Octreotide group and 1 participant in the placebo group without liver involvement at the beginning of the study were excluded from this analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="11.0" upper_limit="28.8"/>
                    <measurement group_id="O2" value="6.0" lower_limit="3.7" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rates According to World Health Organization (WHO) Criteria at 3 Month Intervals</title>
        <time_frame>at 3 month intervals</time_frame>
        <posting_date>12/2014</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Response at 3 Month Intervals</title>
        <time_frame>at 3 month intervals up to 18 moths</time_frame>
        <posting_date>12/2014</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Control at 3 Month Intervals</title>
        <time_frame>at 3 month intervals up to 18 moths</time_frame>
        <posting_date>12/2014</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (Standardized Questionnaire) at Three-month Intervals in Comparison With the Start of the Study</title>
        <time_frame>at three-month intervals</time_frame>
        <posting_date>12/2014</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <time_frame>at least on a monthly basis</time_frame>
        <posting_date>12/2014</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Octreotide LAR (SMS995)</title>
          <description>Octreotide LAR (Long-acting release) 30 mg intramuscularly every 28 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Sodium chloride intramuscularly every 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorder</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematopoietic system</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Health</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carmen Schade-Brittinger</name_or_title>
      <organization>KKS Marburg</organization>
      <phone>0049-6421-2866458</phone>
      <email>carmen.brittinger@kks.uni-marburg.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

